ISS-cat allergen conjugate - Dynavax
Latest Information Update: 16 Apr 2008
At a glance
- Originator Dynavax Technologies
- Mechanism of Action Immunosuppressants; Toll-like receptor 9 agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Hypersensitivity
Most Recent Events
- 16 Apr 2008 Preclinical development is ongoing
- 30 Jul 2007 Preclinical trials in Allergy in USA (unspecified route)